Trade Karyopharm - KPTI CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.06 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Karyopharm Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 0.68 |
Open* | 0.68 |
1-Year Change* | -86.18% |
Day's Range* | 0.65 - 0.7 |
52 wk Range | 0.67-5.42 |
Average Volume (10 days) | 782.49K |
Average Volume (3 months) | 25.36M |
Market Cap | 84.55M |
P/E Ratio | -100.00K |
Shares Outstanding | 114.53M |
Revenue | 145.87M |
EPS | -1.32 |
Dividend (Yield %) | N/A |
Beta | -0.19 |
Next Earnings Date | Feb 13, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Nov 27, 2023 | 0.68 | -0.02 | -2.86% | 0.70 | 0.73 | 0.68 |
Nov 24, 2023 | 0.71 | 0.02 | 2.90% | 0.69 | 0.77 | 0.69 |
Nov 22, 2023 | 0.68 | -0.04 | -5.56% | 0.72 | 0.72 | 0.68 |
Nov 21, 2023 | 0.71 | -0.02 | -2.74% | 0.73 | 0.77 | 0.71 |
Nov 20, 2023 | 0.76 | 0.01 | 1.33% | 0.75 | 0.79 | 0.74 |
Nov 17, 2023 | 0.75 | 0.07 | 10.29% | 0.68 | 0.76 | 0.68 |
Nov 16, 2023 | 0.67 | -0.04 | -5.63% | 0.71 | 0.73 | 0.67 |
Nov 15, 2023 | 0.70 | -0.05 | -6.67% | 0.75 | 0.77 | 0.70 |
Nov 14, 2023 | 0.73 | 0.01 | 1.39% | 0.72 | 0.76 | 0.71 |
Nov 13, 2023 | 0.72 | 0.03 | 4.35% | 0.69 | 0.73 | 0.66 |
Nov 10, 2023 | 0.68 | -0.01 | -1.45% | 0.69 | 0.70 | 0.65 |
Nov 9, 2023 | 0.67 | -0.06 | -8.22% | 0.73 | 0.74 | 0.65 |
Nov 8, 2023 | 0.72 | -0.05 | -6.49% | 0.77 | 0.77 | 0.71 |
Nov 7, 2023 | 0.77 | -0.09 | -10.47% | 0.86 | 0.86 | 0.77 |
Nov 6, 2023 | 0.86 | -0.05 | -5.49% | 0.91 | 0.94 | 0.86 |
Nov 3, 2023 | 0.86 | 0.11 | 14.67% | 0.75 | 0.88 | 0.75 |
Nov 2, 2023 | 0.74 | -0.04 | -5.13% | 0.78 | 0.82 | 0.72 |
Nov 1, 2023 | 0.77 | -0.08 | -9.41% | 0.85 | 0.85 | 0.76 |
Oct 31, 2023 | 0.84 | 0.07 | 9.09% | 0.77 | 0.86 | 0.77 |
Oct 30, 2023 | 0.79 | -0.03 | -3.66% | 0.82 | 0.87 | 0.79 |
Karyopharm Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, November 29, 2023 | ||
Time (UTC) 21:00 | Country US
| Event Karyopharm Therapeutics Inc at Piper Sandler Healthcare Conference Karyopharm Therapeutics Inc at Piper Sandler Healthcare ConferenceForecast -Previous - |
Tuesday, February 13, 2024 | ||
Time (UTC) 13:30 | Country US
| Event Q4 2023 Karyopharm Therapeutics Inc Earnings Release Q4 2023 Karyopharm Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 157.074 | 209.819 | 108.085 | 40.893 | 30.336 |
Revenue | 157.074 | 209.819 | 108.085 | 40.893 | 30.336 |
Total Operating Expense | 299.276 | 308.09 | 279.935 | 230.168 | 210.219 |
Selling/General/Admin. Expenses, Total | 145.401 | 143.846 | 126.417 | 105.421 | 48.847 |
Research & Development | 148.662 | 160.842 | 150.813 | 122.34 | 161.372 |
Operating Income | -142.202 | -98.271 | -171.85 | -189.275 | -179.883 |
Interest Income (Expense), Net Non-Operating | -22.637 | -25.464 | -24.32 | -10.225 | 1.535 |
Other, Net | -0.083 | -0.085 | 0.206 | -0.05 | -0.033 |
Net Income Before Taxes | -164.922 | -123.82 | -195.964 | -199.55 | -178.381 |
Net Income After Taxes | -165.291 | -124.088 | -196.273 | -199.59 | -178.407 |
Net Income Before Extra. Items | -165.291 | -124.088 | -196.273 | -199.59 | -178.407 |
Net Income | -165.291 | -124.088 | -196.273 | -199.59 | -178.407 |
Income Available to Common Excl. Extra. Items | -165.291 | -124.088 | -196.273 | -199.59 | -178.407 |
Income Available to Common Incl. Extra. Items | -165.291 | -124.088 | -196.273 | -199.59 | -178.407 |
Diluted Net Income | -165.291 | -124.088 | -196.273 | -199.59 | -178.407 |
Diluted Weighted Average Shares | 81.871 | 75.218 | 72.044 | 61.9554 | 56.7997 |
Diluted EPS Excluding Extraordinary Items | -2.01892 | -1.64971 | -2.72435 | -3.22151 | -3.14098 |
Diluted Normalized EPS | -2.01892 | -1.64971 | -2.72435 | -3.22151 | -3.14098 |
Cost of Revenue, Total | 5.213 | 3.402 | 2.705 | 2.407 | |
Gross Profit | 151.861 | 206.417 | 105.38 | 38.486 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 37.579 | 38.698 | 33.58 | 36.145 | 39.679 |
Revenue | 37.579 | 38.698 | 33.58 | 36.145 | 39.679 |
Cost of Revenue, Total | 1.194 | 1.351 | 1.868 | 0.98 | 0.939 |
Gross Profit | 36.385 | 37.347 | 31.712 | 35.165 | 38.74 |
Total Operating Expense | 67.152 | 69.597 | 67.449 | 66.984 | 82.587 |
Selling/General/Admin. Expenses, Total | 34.481 | 35.907 | 34.649 | 34.645 | 37.339 |
Research & Development | 31.477 | 32.339 | 30.932 | 31.359 | 44.309 |
Operating Income | -29.573 | -30.899 | -33.869 | -30.839 | -42.908 |
Interest Income (Expense), Net Non-Operating | -2.96 | -2.909 | -4.551 | -5.456 | -6.02 |
Other, Net | 0.03 | -0.264 | -0.013 | 0.016 | -0.013 |
Net Income Before Taxes | -32.503 | -34.072 | -38.433 | -36.279 | -48.941 |
Net Income After Taxes | -32.63 | -34.126 | -38.506 | -36.324 | -49.062 |
Net Income Before Extra. Items | -32.63 | -34.126 | -38.506 | -36.324 | -49.062 |
Net Income | -32.63 | -34.126 | -38.506 | -36.324 | -49.062 |
Income Available to Common Excl. Extra. Items | -32.63 | -34.126 | -38.506 | -36.324 | -49.062 |
Income Available to Common Incl. Extra. Items | -32.63 | -34.126 | -38.506 | -36.324 | -49.062 |
Diluted Net Income | -32.63 | -34.126 | -38.506 | -36.324 | -49.062 |
Diluted Weighted Average Shares | 114.207 | 113.481 | 90.025 | 80.21 | 79.651 |
Diluted EPS Excluding Extraordinary Items | -0.28571 | -0.30072 | -0.42773 | -0.45286 | -0.61596 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.28571 | -0.30072 | -0.42773 | -0.45286 | -0.61596 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 350.162 | 275.606 | 276.531 | 278.57 | 334.612 |
Cash and Short Term Investments | 277.967 | 228.615 | 249.24 | 261.956 | 328.199 |
Cash & Equivalents | 135.188 | 190.459 | 85.918 | 128.858 | 118.021 |
Short Term Investments | 142.779 | 38.156 | 163.322 | 133.098 | 210.178 |
Prepaid Expenses | 19.821 | 14.039 | 9.285 | 7.289 | 6.413 |
Total Assets | 358.172 | 305.305 | 313.05 | 294.963 | 341.192 |
Property/Plant/Equipment, Total - Net | 7.377 | 9.557 | 11.582 | 13.663 | 3.863 |
Property/Plant/Equipment, Total - Gross | 14.022 | 15.614 | 16.77 | 17.905 | 7.156 |
Accumulated Depreciation, Total | -6.645 | -6.057 | -5.188 | -4.242 | -3.293 |
Long Term Investments | 0 | 24.215 | 2.016 | 2.001 | |
Other Long Term Assets, Total | 0.633 | 20.142 | 0.722 | 0.714 | 0.716 |
Total Current Liabilities | 65.908 | 73.718 | 60.203 | 46.35 | 46.904 |
Accounts Payable | 2.773 | 1.603 | 4.45 | 0.985 | 4.332 |
Accrued Expenses | 61.287 | 71.437 | 54.847 | 42.524 | 32.493 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 1.848 | 0.678 | 0.906 | 2.841 | 10.079 |
Total Liabilities | 374.828 | 384.978 | 262.504 | 245.189 | 158.022 |
Total Long Term Debt | 302.823 | 302.291 | 191.016 | 183.445 | 102.664 |
Other Liabilities, Total | 6.097 | 8.969 | 11.285 | 15.394 | 8.454 |
Total Equity | -16.656 | -79.673 | 50.546 | 49.774 | 183.17 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.012 | 0.008 | 0.007 | 0.007 | 0.006 |
Additional Paid-In Capital | 1327.91 | 1098.78 | 1119.63 | 923.142 | 857.156 |
Retained Earnings (Accumulated Deficit) | -1343.94 | -1178.65 | -1069.61 | -873.338 | -673.748 |
Other Equity, Total | -0.638 | 0.191 | 0.518 | -0.037 | -0.244 |
Total Liabilities & Shareholders’ Equity | 358.172 | 305.305 | 313.05 | 294.963 | 341.192 |
Total Common Shares Outstanding | 113.213 | 75.746 | 73.923 | 65.3705 | 60.8293 |
Other Current Assets, Total | 1.064 | 6.349 | 2.481 | 1.117 | 0 |
Long Term Debt | 302.823 | 302.291 | 191.016 | 183.445 | 102.664 |
Total Receivables, Net | 47.086 | 22.497 | 12.881 | 7.862 | |
Accounts Receivable - Trade, Net | 47.086 | 22.497 | 12.881 | 7.862 | |
Total Inventory | 4.224 | 4.106 | 2.644 | 0.346 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 263.222 | 291.381 | 318.541 | 350.162 | 222.677 |
Cash and Short Term Investments | 208.315 | 236.765 | 260.384 | 277.967 | 148.381 |
Cash & Equivalents | 43.655 | 80.894 | 84.062 | 135.188 | 71.351 |
Short Term Investments | 164.66 | 155.871 | 176.322 | 142.779 | 77.03 |
Total Receivables, Net | 37.923 | 32.28 | 35.2 | 47.086 | 27.446 |
Accounts Receivable - Trade, Net | 37.923 | 32.28 | 35.2 | 47.086 | 27.446 |
Total Inventory | 3.105 | 3.672 | 3.827 | 4.224 | 4.249 |
Prepaid Expenses | 13.334 | 18.097 | 18.284 | 19.821 | 41.521 |
Other Current Assets, Total | 0.545 | 0.567 | 0.846 | 1.064 | 1.08 |
Total Assets | 269.96 | 297.83 | 325.8 | 358.172 | 231.236 |
Property/Plant/Equipment, Total - Net | 5.482 | 6.062 | 6.625 | 7.377 | 7.933 |
Long Term Investments | |||||
Other Long Term Assets, Total | 1.256 | 0.387 | 0.634 | 0.633 | 0.626 |
Total Current Liabilities | 62.079 | 58.928 | 61.555 | 65.908 | 61.761 |
Accounts Payable | 0.943 | 2.287 | 9.045 | 2.773 | 0.813 |
Accrued Expenses | 58.908 | 54.892 | 50.009 | 61.287 | 58.486 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 2.228 | 1.749 | 2.501 | 1.848 | 2.462 |
Total Liabilities | 370.356 | 369.078 | 370.974 | 374.828 | 371.516 |
Total Long Term Debt | 303.181 | 303.215 | 303.024 | 302.823 | 302.892 |
Long Term Debt | 303.181 | 303.215 | 303.024 | 302.823 | 302.892 |
Other Liabilities, Total | 5.096 | 6.935 | 6.395 | 6.097 | 6.863 |
Total Equity | -100.396 | -71.248 | -45.174 | -16.656 | -140.28 |
Common Stock | 0.012 | 0.012 | 0.012 | 0.012 | 0.008 |
Additional Paid-In Capital | 1345.54 | 1340.22 | 1333.3 | 1327.91 | 1165.9 |
Retained Earnings (Accumulated Deficit) | -1445.2 | -1410.69 | -1378.06 | -1343.94 | -1305.43 |
Other Equity, Total | -0.742 | -0.783 | -0.419 | -0.638 | -0.752 |
Total Liabilities & Shareholders’ Equity | 269.96 | 297.83 | 325.8 | 358.172 | 231.236 |
Total Common Shares Outstanding | 114.523 | 114.34 | 113.971 | 113.213 | 81.027 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -165.291 | -124.088 | -196.273 | -199.59 | -178.407 |
Cash From Operating Activities | -149.554 | -107.116 | -160.234 | -190.822 | -159.117 |
Cash From Operating Activities | 0.621 | 0.789 | 0.972 | 0.974 | 0.735 |
Non-Cash Items | 35.105 | 39.372 | 33.726 | 21.102 | 18.724 |
Changes in Working Capital | -19.989 | -23.189 | 1.341 | -13.308 | -0.169 |
Cash From Investing Activities | -104.256 | 141.84 | -53.685 | 78.45 | -107.664 |
Capital Expenditures | -0.118 | -0.212 | -0.145 | -0.206 | -2.363 |
Other Investing Cash Flow Items, Total | -104.138 | 142.052 | -53.54 | 78.656 | -105.301 |
Cash From Financing Activities | 193.738 | 73.648 | 172.083 | 124.305 | 316.109 |
Financing Cash Flow Items | 0 | 60 | |||
Issuance (Retirement) of Stock, Net | 193.738 | 13.648 | 172.083 | 50.696 | 149.224 |
Foreign Exchange Effects | -0.488 | -0.048 | 0.268 | 0.019 | -0.078 |
Net Change in Cash | -60.56 | 108.324 | -41.568 | 11.952 | 49.25 |
Issuance (Retirement) of Debt, Net | 0 | 73.609 | 166.885 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -34.126 | -165.291 | -126.785 | -90.461 | -41.399 |
Cash From Operating Activities | -18.91 | -149.554 | -122.711 | -94.341 | -59.197 |
Cash From Operating Activities | 0.29 | 0.621 | 0.508 | 0.326 | 0.177 |
Non-Cash Items | 4.468 | 35.105 | 29.464 | 22.754 | 7.577 |
Changes in Working Capital | 10.458 | -19.989 | -25.898 | -26.96 | -25.552 |
Cash From Investing Activities | -32.388 | -104.256 | -38.958 | -50.631 | -14.035 |
Capital Expenditures | 0 | -0.118 | -0.118 | -0.079 | -0.079 |
Other Investing Cash Flow Items, Total | -32.388 | -104.138 | -38.84 | -50.552 | -13.956 |
Cash From Financing Activities | 0 | 193.738 | 37.895 | 32.096 | 30.783 |
Issuance (Retirement) of Stock, Net | 0 | 193.738 | 37.895 | 32.096 | 30.783 |
Foreign Exchange Effects | -0.045 | -0.488 | -0.614 | -0.544 | -0.09 |
Net Change in Cash | -51.343 | -60.56 | -124.388 | -113.42 | -42.539 |
Financing Cash Flow Items | 0 | 0 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 7.9037 | 9038183 | 2057417 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 7.5805 | 8668620 | 1180292 | 2023-06-30 | LOW |
Avidity Partners Management LP | Hedge Fund | 7.3194 | 8370100 | -1263811 | 2023-06-30 | HIGH |
Palo Alto Investors LP | Hedge Fund | 4.9634 | 5675876 | 0 | 2023-06-30 | LOW |
Chione, Ltd. | Corporation | 3.8477 | 4400000 | -600000 | 2022-12-31 | LOW |
Citadel Advisors LLC | Hedge Fund | 2.7543 | 3149682 | -452778 | 2023-06-30 | LOW |
Marshall Wace LLP | Investment Advisor/Hedge Fund | 2.1372 | 2443997 | 459091 | 2023-06-30 | HIGH |
ExodusPoint Capital Management, LP | Hedge Fund | 2.0834 | 2382451 | 2382451 | 2023-06-30 | HIGH |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.9347 | 2212367 | -7963622 | 2023-06-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.8688 | 2137094 | 365361 | 2023-06-30 | LOW |
Opaleye Management Inc. | Hedge Fund | 1.5609 | 1785000 | -1025800 | 2023-06-30 | MED |
Delphi Ventures L.P. | Venture Capital | 1.5078 | 1724222 | -538784 | 2023-03-20 | LOW |
BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 1.3258 | 1516152 | 195001 | 2023-06-30 | LOW |
C WorldWide Asset Management Fondsmaeglerselskab A/S | Investment Advisor | 1.3117 | 1500000 | 0 | 2023-06-30 | LOW |
Candriam Belgium S.A. | Investment Advisor/Hedge Fund | 1.2555 | 1435694 | -99332 | 2023-06-30 | LOW |
AIGH Capital Management, LLC. | Private Equity | 1.1609 | 1327493 | 1327493 | 2023-06-30 | MED |
Goldman Sachs & Company, Inc. | Research Firm | 1.089 | 1245318 | -74332 | 2023-06-30 | MED |
Millennium Management LLC | Hedge Fund | 1.0067 | 1151241 | 1137478 | 2023-06-30 | HIGH |
Tejara Capital Ltd. | Investment Advisor | 1.0004 | 1143991 | 642429 | 2023-06-30 | HIGH |
Candriam Luxembourg S.A. | Investment Advisor | 0.9975 | 1140630 | -95000 | 2023-09-30 | MED |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Karyopharm Company profile
About Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (CRM1). Its lead compound, XPOVIO (selinexor), is marketed in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). NEXPOVIO (selinexor), the brand name for XPOVIO in Europe, in combination with dexamethasone to treat adult patients with multiple myeloma. It is also developing treatments for other diseases.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Karyopharm Therapeutics Inc revenues increased 94% to $209.8M. Net loss decreased 37% to $124.1M. Revenues reflect License and other revenue increase from $31.9M to $111.4M, Product revenue, net increase of 29% to $98.4M. Lower net loss reflects Interest expense decrease of 4% to $26M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.72 to -$1.65.
Equity composition
Common Stock $0.0001 Par, 11/13, 100M auth., 28,729,593 issd. Insiders own approx. 76.33%
Industry: | Bio Therapeutic Drugs |
85 Wells Ave
NEWTON CENTER
MASSACHUSETTS 02459-3298
US
Income Statement
- Annual
- Quarterly
News

A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023
Gold Rises as Traders price-in Fed Rate Cuts
Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.
13:17, 20 November 2023
XAU/USD Latest: Gold advances as weaker data weighs on US yields
Gold moves higher as softer economic data weighs on US yields and the dollar
13:43, 17 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com